Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor c…
| Periodo | 2026-11 | 2026-09 |
|---|---|---|
| Real | — | $-27.59 |
| Estimado | $-0.59 | $-0.66 |
| Sorpresa | — | -4080.3% |
| Métrica | LTGO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | — | -30.9% | — |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
Latigo Biotherapeutics, Inc. cotiza a 14.00 USD y tiene una capitalización bursátil de $928M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud